Pathways to new drug discovery in neuropsychiatry by Berk, Michael
	 	
	
 
 
 
This is the published version:  
 
	
Berk,	Michael	2012,	Pathways	to	new	drug	discovery	in	neuropsychiatry,	BMC	medicine,	vol.	10,	
no.	151,	pp.	1‐4.	
	
	
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30052722	
	
	
	
Reproduced	with	the	kind	permission	of	the	copyright	owner.		
	
Copyright	:	2012,	BioMed	Central 
	
COMMENTARY Open Access
Pathways to new drug discovery in
neuropsychiatry
Michael Berk1,2,3,4,5
Abstract
There is currently a crisis in drug discovery for
neuropsychiatric disorders, with a profound, yet
unexpected drought in new drug development across
the spectrum. In this commentary, the sources of this
dilemma and potential avenues to redress the issue
are explored. These include a critical review of
diagnostic issues and of selection of participants for
clinical trials, and the mechanisms for identifying new
drugs and new drug targets. Historically, the vast
majority of agents have been discovered
serendipitously or have been modifications of existing
agents. Serendipitous discoveries, based on astute
clinical observation or data mining, remain a valid
option, as is illustrated by the suggestion in the paper
by Wahlqvist and colleagues that treatment with
sulfonylurea and metformin reduces the risk of
affective disorder. However, the identification of
agents targeting disorder-related biomarkers is
currently proving particularly fruitful. There is
considerable hope for genetics as a purist,
pathophysiologically valid pathway to drug discovery;
however, it is unclear whether the science is ready to
meet this promise. Fruitful paradigms will require a
break from the orthodoxy, and creativity and risk may
well be the fingerprints of success.
See related article http://www.biomedcentral.com/
1741-7015/10/150
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Introduction
Before applying a microscope to a problem, it is always
wise to first use a wide-angle lens. In psychiatric disorders,
as in most of medicine, the two things that matter most to
people with disorders are the availability of effective treat-
ments for those disorders and the capacity to prevent
these disorders occurring in the first instance. With regard
to the latter, psychiatry is only beginning to develop an
evidence base of potentially plastic risk factors for the
development of common mental disorders. Existing treat-
ments for most major psychiatric disorders are limited in
terms of their efficacy and tolerability. The situation in
terms of new drug development is best summarized by
Steven Hyman, a previous director of the US National
Institute of Mental Health (NIMH) director, who stated
that, ‘Drug discovery is at a near standstill for treating psy-
chiatric disorders such as schizophrenia, bipolar disorder,
depression, and common forms of autism. Despite high
prevalence and unmet medical need, major pharmaceuti-
cal companies are deemphasizing or exiting psychiatry,
thus removing significant capacity from efforts to discover
new medicines’ [1].
Pathways to drug discovery
How did we get into this pickle? And how can we extricate
ourselves? To answer this, it is necessary we look at the
pathways to drug discovery and critically analyze which of
these are fruitful paths to drug discovery and what new
avenues might be open. The initial path has been that of
serendipity. Almost all psychotropic agents have been dis-
covered accidentally, their mechanisms of action reverse-
engineered, and new agents developed that, in some cases,
have improved on the originals. Lithium, the antipsycho-
tics, and the antidepressants all fall into this class. Indeed,
most of our knowledge of the neurobiology of neuropsy-
chiatric disorders derives from this process; this includes
the dopamine theory of schizophrenia and the monoamine
theory of antidepressants [2]. Sadly, the rewards deriving
from this path seem to be dwindling. At least part of the
problem arises from the fact that these agents have been
utilized for proof of concept in animal models of these dis-
orders, and these models in a circular manner seem toCorrespondence: MIKEBE@BarwonHealth.org.au1Deakin University, School of Medicine, Barwon Health, P.O. Box 291,
Geelong, 3220, Australia
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reflect the profile of the original agents and are of dubious
value in detecting novel mechanisms [3].
Nevertheless, both astute clinical examination, and
observational studies of unexpected benefits of agents
used for other indications, remain valuable avenues for
drug discovery, despite their lack of a primary, pathophy-
siologically grounded scientific process. In this context,
the paper by Wahlqvist et al. [4], which used a retrospec-
tive case-control study of data from the Taiwanese
National Health Insurance database to examine whether
people taking a sulfonylurea and/or metformin had a
lower incidence of depression, is noteworthy. The
authors reported that patients with diabetes taking sulfo-
nylurea or metformin had a lower incidence of depres-
sion than people not taking these anti-diabetic agents [4].
This is not entirely unexpected. There are published data
suggesting that pioglitazone, an oral anti-diabetic agent,
also has antidepressant properties [5]. The hypothesis
leading the authors of this study on pioglitazone was that
this agent has anti-inflammatory properties, which
remains a plausible explanation for its efficacy profile [5].
Nevertheless, it is entirely plausible that this group of
agents may be operating through entirely different path-
ways, which substantially increases the gravity of the
finding. Shared operative pathways between depression
and diabetes have been indicated by a number of studies
that suggest that depression and diabetes are risk factors
for each other [6,7]. It is noteworthy that oral hypoglyce-
mic agents might have protective effects against other
neuropsychiatric disorders, including dementia and Par-
kinson’s disease [8,9], suggesting that these agents could
have effects on pathways to neuroprogression that may
be overlapping in these disorders.
Another promising pathway of new drug discovery for
neuropsychiatric disorders is to target biomarkers known
to be dysregulated in these disorders. The most promising
of these seems to be the inflammatory and oxidative path-
ways. As exemplars of this approach, N-acetyl cysteine, a
precursor of glutathione, the brain’s principal redox sca-
venger, has been shown to be efficacious for a diverse
range of neuropsychiatric disorders, including schizophre-
nia, bipolar disorder, autism, and addictions [10,11].
Exploring the use of agents with anti-inflammatory prop-
erties has also been fruitful, with agents as diverse as sta-
tins, aspirin, celecoxib, and pioglitazone showing promise
[12,13]. It can be argued that this is, at the present time,
the most productive route.
The revolution in genetics has opened an entirely new
vista for new drug discoveries. Indeed, many of the most
influential funding agencies such as the National Insti-
tutes of Health (NIH) in the USA are prioritizing this
avenue of research. The promise of genetics is consider-
able, because of the lack of a coherent pathophysiology
for almost all psychiatric disorders and hence rational
drug targets for such disorders. Although psychiatric
genetics remains in its infancy, a number of promising
candidates have emerged, including the calcium channel
proteins CACNA1 (Calcium channel, voltage-dependent,
T type, alpha 1) and IKCNH2 (potassium voltage-gated
channel, subfamily H (eag-related), member 2), vasoac-
tive intestinal peptide 2, DISC1 (Disrupted in schizophre-
nia 1) and Ankyrin-3 [14]. Nevertheless, several caveats
are necessary. Very few of the genes of interest involve
traditional neurotransmitter targets, the source of most
current psychotropics. Hundreds of genes are involved,
all with very small effects, and their physiology and
pathophysiology remains unknown. I am constantly
reminded of the day, as a young neurology registrar, that
the professor walked in, enthused with excitement, to tell
us that the gene for Huntington’s disease (HD) had been
discovered. The experts were sure, given that there is a
single gene coding for a single protein and accounting for
100% of the disease expression, that a treatment for HD
would be found within a year or two. It is many decades
since that day, and no treatment has been forthcoming.
As psychiatric genetics is vastly more complicated, hopes
have to be cautious at best. Although genetics offers an
avenue of scientific purity, it is likely that considerable
time will need to pass before the technology is able to
utilize the un-translated genetic data to develop new psy-
chiatric treatments.
In the context of drug discovery, a word about diagnosis
is appropriate. Current diagnostic classifications are
entirely based on phenomenology. In no other branch of
medicine does phenomenology track pathology. There are
multiple causes of every symptom and diseases that can be
expressed with a dizzying array of seemingly unrelated
phenomenology. Highlighting the limitations of our cur-
rent classification, biomarkers including cognition, neuroi-
maging, inflammation, oxidative stress, and neurotropins
show absolutely no respect for the current classifications,
nor might we expect that they should [15,16]. In this
regard, the use of traditional diagnostic categories for drug
discovery is more of a blinker than a lens, and approaches
that eschew current classifications need to be explored.
There is a bizarre paradox that hard-won improvements
in service delivery, diagnosis, and access to treatments
might be hampering the ability to discover novel therapies.
For example, in antidepressant clinical studies, drug pla-
cebo differences have been shrinking by about two points
per year over the past four or five decades. Indeed, it is
becoming increasingly difficult to demonstrate the efficacy
of even established antidepressants. This is highly unlikely
to be entirely due to our inability to discover useful com-
pounds; it is much more likely to be powerfully influenced
by an artifact of the process used in conduct of clinical
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trials. Fifty years ago, when the first studies commenced,
severely ill people, who had not previously been exposed
to treatments, were the primary study population. Hence,
only small studies were required to show large clinical
effects. Two parallel processes have occurred since then.
First, diagnostic categories are being used for increasingly
mildly ill populations, leading to a growth in perceived pre-
valence, but a dilution of ‘endogenous’ or biologic factors.
Second, service filters have a powerful effect on study
populations. Clear clinical-care pathways exist for
depressed individuals, for example, who are likely to seek
treatment in primary-care settings, which have been sub-
stantially upskilled of late. Treatment-responsive individuals
benefitting from primary or secondary care are conse-
quently unavailable for clinical trials. Thus, clinical-trial
populations tend to select individuals who have failed on or
are disillusioned with existing therapeutic options [17]. It is
unlikely that our capacity to develop novel therapies is
going to increase unless we are able to address these funda-
mental issues.
Future direction and conclusions
The receding tide of infective disorders, trauma, and
many major medical disorders, resulting from improved
general medical preventative, diagnostic and treatment
strategies, leaves psychiatric disorders exposed as the pre-
dominant burden of disability in the developed world.
The imperative to discover new treatments is clear, not
only because of the aforementioned issues, but because
of the limitations of established treatments. It is clear
that we need to move beyond high-throughput screening
of compounds aimed at historical targets; we need to
explore fundamentally different pathways to drug discov-
ery such as genetics. However, as noted, this is a high-
risk, very low-probability, albeit high-return scenario.
Increasing attention to biomarker-indicated targets is
likely to be a very promising avenue, but we must not
lose sight of the fact that serendipity and keen clinical
and scientific observation remains the most fruitful path-
way for the discovery of novel therapies.
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